A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea.
Latest Information Update: 04 Apr 2022
At a glance
- Drugs Fedratinib (Primary)
- Indications Essential thrombocythaemia; Polycythaemia vera
- Focus Therapeutic Use
- Sponsors Sanofi
- 02 Apr 2022 This trial has been completed in France (Date of the global end of the trial : 19-May-2014), according to European Clinical Trials Database record.
- 18 Nov 2013 Status changed from recruiting to discontinued, according to a Sanofi media release. Development of fedratinib has been discontinued.
- 09 Jan 2013 The number of treatment arms changed from 3 to 4. Now the treatment arm consist of an extra arm of 600 mg.